Concord Biotech Q1 FY26 Concall Decoded: Injectables Burn Cash, APIs Take a Nap

1. Opening Hook

You know that one cousin who aces every exam but flops at family dance competitions? That’s Concord this quarter. FDA, EU, Russian GMP inspections cleared like a boss — but revenue slipped 5%, APIs yawned, and new injectables sucked EBITDA dry. Management’s answer: “Don’t look at quarters, look at decades.” Investors, meanwhile, looked at margins diving from 38% to 30% and said, “Bhai, we can’t pay rent in decades.” Keep reading — the CDMO story and 25% CAGR dream make this a biotech soap opera worth watching.

2. At a Glance

• Revenue ₹204 cr, -5% YoY – APIs skipped gym this quarter.
• API revenue ₹154 cr, -10% YoY – Blamed “lumpiness,” aka clients ghosted.
• Formulation revenue ₹50 cr, +12% YoY – Small but energetic kid in the family.
• EBITDA ₹61 cr, -25% YoY – New injectable facility burnt pockets.
• Margins 30.1% vs 37.7% YoY – Once a Ferrari, now driving an Alto.
• PAT ₹44 cr, -27% YoY – Profits went on a detox retreat.
• Exports 45% (15% U.S.) – Still mostly Indian at heart.

3. Management’s Key Commentary

Quote: “Q1 was impacted by revenue lumpiness.”
(Translation: Clients bought too much last quarter, now they’re on a diet.)

Quote: “Excluding injectables, margins were 37%, flat YoY.”
(Translation: Please ignore the cash furnace we just switched on.)

Quote: “Teriflunomide approval in U.S. is a big milestone.”
(Translation: Finally, something that sounds cool in the press release.)

Quote: “Stellon Biotech will give us a direct U.S. presence.”
(Translation: Middlemen fired, now we get yelled at by U.S. clients directly.)

Quote: “CDMO business launched in U.S., first orders shipped.”
(Translation: New side hustle unlocked — pharma Uber Eats.)

Quote: “25% CAGR possible over 5 years.”
(Translation: Historical 18% growth + Excel optimism = 25%.)

Quote: “Injectables will break even by FY26 end, hopefully.”
(Translation: Please light an agarbatti at the Valthera plant.)

4. Numbers Decoded